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Abstract
Background: New high-throughput sequencing technologies promise a very sensitive and high-resolution analysis
of DNA methylation patterns in quantitative terms. However, a detailed and comprehensive comparison with
existing validated DNA methylation analysis methods is not yet available. Therefore, a systematic cross-validation of
454 sequencing and conventional pyrosequencing, both of which offer exact quantification of methylation levels
with a single CpG dinucleotide resolution, was performed.
Results: To this end the methylation patterns of 12 loci (GSTπ1, p16
INK4a, RASSF1A, SOCS1, MAL, hsa-mir-1-1, hsa-mir-
9-3, hsa-mir-34a, hsa-mir-596, hsa-mir-663, MINT31, and LINE-1) were analyzed in ten primary hepatocellular
carcinoma specimens. After applying stringent quality control criteria, 35749 sequences entered further analysis.
The methylation level of individual CpG dinucleotides obtained by 454 sequencing was systematically compared
with the corresponding values obtained by conventional pyrosequencing. Statistical analyses revealed an excellent
concordance of methylation levels for all individual CpG dinucleotides under study (r
2 = 0.927).
Conclusions: Our results confirm that 454 sequencing of bisulfite treated genomic DNA provides reliable high
quality quantitative methylation data and identify MAL, hsa-mir-9-3, hsa-mir-596, and hsa-mir-663 as new targets of
aberrant DNA methylation in human hepatocelluar carcinoma. In addition, the single molecule resolution of 454
sequencing provides unprecedented information about the details of DNA methylation pattern heterogeneity in
clinical samples.
Background
Traditionally, cancer has been regarded as a disease that
is driven by progressive genetic abnormalities including
mutations and chromosomal aberrations in tumor-sup-
pressor genes and oncogenes. However, it has become
clear that cancer is also driven by ‘epigenetic changes’–
patterns of altered gene expression that are mediated by
mechanisms that do not affect the primary DNA
sequence [1]. The main epigenetic mechanisms are
DNA methylation, histone modifications and non-cod-
ing RNAs. DNA methylation represses transcription
directly, by inhibiting the binding of specific transcrip-
tion factors, and indirectly, by recruiting methyl-CpG-
binding proteins and their associated repressive chroma-
tin remodeling activities [2]. Since the hypermethylation
of CpG islands is relatively rare in normal cells, and
often an early event in transformation, it represents a
promising biomarker for early cancer detection [3].
The methylation status of DNA can be detected by
several methods [4]. To measure methylation levels,
bisulfite conversion has been combined with restriction
analysis (COBRA [5]), base-specific cleavage and mass
spectrometry [6], real-time PCR (MethyLight, [7]), and
pyrosequencing [8]. However, not all of these methods
provide quantitative data with a single CpG resolution.
The technique considered by many in the field as the
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examines multiple subclones of a bisulfite PCR product
[9]. However, if only 5 - 10 clones are sequenced (as in
most published studies) this approach is at best semi-
quantitative and not very sensitive.
Over the past five years, DNA sequencing technology
has evolved rapidly. Among others, a novel massively
parallel sequencing-by-synthesis method was introduced
that is based on pyrosequencing in picoliter-scale reac-
tions ("454 sequencing”). The 454 technology generates
~ 400,000 reads per instrument-run at lengths of 200 to
300 bp with an accuracy of 99.6% [10]. With the intro-
duction of new reagents the average read length is
increased to 400 - 500 bp [11]. In principle, the large
number of sequence reads per amplicon (dozens or even
hundreds) offers the opportunity to obtain precise quan-
titative methylation data for every single CpG site con-
tained within the amplicon. To the best of our
knowledge, this has not yet been studied comprehen-
sively employing rigorous statistical tools.
Therefore, we cross-validated 454 amplicon bisulfite
sequencing and conventional pyrosequencing, which is a
well established and validated, highly quantitative
method for the exact quantification of DNA methylation
patterns with single CpG resolution by measuring the
methylation level of 89 CpG dinucleotides from 12 loci
in 10 patient samples.
Results
Selection of loci
In order to explore the feasibility of quantitative methy-
lation studies using 454 sequencing, a range of genomic
loci was selected for in-depth analysis: tumor-suppressor
genes reported to be frequently hypermethylated in
hepatocellular carcinoma (p16
INK4a,R A S S F 1 A ,S O C S - 1 ,
GSTπ1, [12] and references therein), classical non-pro-
tein coding CIMP loci also reported to be methylated in
HCC (MINT31, [13]), and microRNA genes identified
by our own group to be aberrantly methylated in HCC
(mir-9-3, mir-34a, mir-596, mir-663). Since Datta et al.
[14] reported aberrant hypermethylation of mir-1-1 in
HCC, this microRNA was also included in the analysis.
In addition, LINE-1 sequences were analyzed because
these repetitive elements often display marked hypo-
methylation and a high sequence heterogeneity which
might be ascertainable by a deep bisulfite sequencing
approach.
Mapping the bisulfite sequencing results
A total of 59,366 sequences were obtained in a single run
using a fraction of a small 454 sequencing plate (25×75
PicoTiterPlate). The maximum expected number of
reads for this setting is about 70,000. The average read
length was 210 bp (range, 53-325 bp). Bioinformatic
analysis consisted of the following three steps: (a) match-
ing each sequence to a unique tagged primer, (b)
mapping the amplicon sequences to the in silico bisulfite-
converted genomic sequence, and (c) compiling sequence
identity, sodium bisulfite conversion efficiency and the
methylation state for each CpG site. (see Materials and
Methods). Of the 59,366 sequences, 50,118 (84.4%) were
mapped to a unique amplicon. The two main sequence
errors observed were the detection of unconverted (or
only partially converted) sequences in individual reads
and small deletions in homopolymeric stretches.
On average, 298 sequence reads were obtained for
each amplicon after filtering. However, the yield per
amplicon was quite variable. The number of reads per
amplicon ranged from 0 to 1487 (mean: 297.9, median:
238.8). A detailed analysis of the number of reads
obtained (after filtering) for each locus in all 10 sam-
ples under study after filtering can be found in Addi-
tional File 1. This variation may be caused by the
secondary structure of each amplicon, amplicon length,
GC content, overall methylation status, and the num-
ber of homopolymers present after bisulfite treatment
which all effect the linker ligation and emulsion PCR
a sw e l la st h ee f f i c i e n c yo fs i n g l em o l e c u l es e q u e n c i n g
reaction. Statistical analysis revealed a significant influ-
ence of the amplicon length on the mean number of
reads (r = -0.81). In contrast, the tendency for second-
ary structure and the GC content show only a weak or
no influence on the number of reads (see Additional
File 2).
Quantitative DNA methylation analysis of individual CpG
islands
Based on the quality of the alignment, reads with a
sequence identity of less than 90% and less than 100%
sodium bisulfite conversion were filtered out. After fil-
tering, a total of 35,749 sequences (60.2%) were used for
computing the methylation level at each individual CpG
dinucleotide. The percentage of methylation at each
CpG site was calculated based on the number of
sequences containing unconverted cytosine (indicating
methylation in the original sequence) versus the total
number of sequences analyzed (Figure 1).
Overall our results for GSTπ1, p16
INK4a, RASSF1A,
SOCS1 and MINT31 are consistent with what others
have previously reported for HCC (Table 1)
[12,13,15-18]. The methylation results for LINE-1 ele-
ments, hsa-mir-1-1 and the newly identified targets
MAL, hsa-mir-9-3, hsa-mir-596,a n dhsa-mir-663,a r e
also compiled in Table 1.
In order to identify allele specific methylation SNPs
were identified in the regions under study. Only for
GSTπ1, miR-663, p16
INK4a,a n dRASSF1A could poten-
tially informative SNPs be found. C/T polymorphisms
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Page 2 of 10were excluded because of the bisulfite treatment and
small deletions/insertions were excluded because of dif-
ficulties discriminating between true deletions/insertions
and 454 sequencing errors. The remaining (small) num-
ber of SNP sites did not reveal anything about allele
specific methylation.
Systematic comparison of 454 sequencing with
conventional pyrosequencing
Conventional pyrosequencing and 454 sequencing can
both be used to quantify the methylation level at every
CpG dinucleotide contained within a given sequence.
Since no systematic cross-validation of these two
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Figure 1 Methylation profile of 12 loci in 10 HCC samples.E a c hcolumn represents a CpG site in each DNA sequence. The names of the
genes are listed above of each set. The sample number is labeled on the left side of each row. The color indicates the methylation level. White,
no methylation; black, methylation. The proportion of black and white in each column indicates the percentage of sequences containing the
methylated CpG sites at this position. The sequencing result of one sample (marked by an asterisk) did not pass the quality control (see
Materials and Methods) and was not included in the figure.
Table 1 Methylation profile of all loci across the 10 HCC samples analyzed in this study
RASSF1A SOCS1 MINT31 LINE1 GSTP1 P16 MAL miR596 miR663 miR9-3 miR1-1 miR34a
1 10% 8% 4% 61% 9% 3% 6% 5% 21% 10% 11% 7%
2 75% 50% 53% 20% 22% 2% 2% 7% 19% 10% 10% 5%
3 81% 79% 67% 20% 21% 52% 2% 4% 24% 8% 18% 3%
4 28% 24% 15% 54% 11% 4% 6% 12% 10% 8% 15% 6%
5 75% 62% 64% 30% 10% 46% 2% 19% 27% 4% 10% 4%
6 88% 61% 76% 54% 74% 1% 30% 50% 79% 25% 20% 2%
7 89% 71% 37% 42% 28% 1% 12% 16% 18% 28% 17% 3%
8 66% 80% 74% 54% 53% 2% 61% 81% 75% 36% 22% 4%
9 84% 8% 64% 53% 67% 1% 38% 50% N/A 58% 24% 3%
10 91% 59% 59% 38% 35% 59% 2% 55% 54% 31% 30% 2%
The percentages are the mean methylation values for a given locus in an individual sample (454 sequencing result).
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Page 3 of 10methods has been performed so far and only limited
data are available about the reliability of 454 sequencing
for the purpose of exact quantification of methylation
levels (see Discussion), a detailed comparison of the
quantitative methylation profile of all 12 loci in all 10
samples was performed. To this end, pyrosequencing
assays were designed in such a way that the sequence to
analyze was contained completely within the amplicon
analyzed by 454 sequencing. Bisulfite treatment for 454
sequencing and conventional pyrosequencing was per-
formed independently for all 10 tumor samples under
study.
Overall, the mean methylation levels obtained by pyro-
sequencing and 454 sequencing showed an excellent
correlation for every gene in all samples (Figure 2). Also
a comparison of the methylation levels of individual
CpG sites showed an excellent concordance between
both methods for all loci under study (Figure 3).
In Figure 4) a Bland-Altman-Plot is shown to demon-
strate the congruence of both methods. In Additional
File 3 the Bland-Altman-Plots for each individual locus
is shown. A difference of less than 10 percentage points
was judged to be acceptable considering the technical
variability of conventional pyrosequencing which is in
the range of 2 - 10 percentage points [19]. The 95% tol-
erance intervals for 10 out of 12 loci are well within the
range of +/- 10 percentage points.
Regression analysis of the methylation levels of all indi-
vidual CpG sites under study obtained independently by
the two methods revealed a very good concordance
(Figure 5, r
2 = 0.927, slope: 0.918, 95% confidence inter-
val: 0.9067 to 0.9300). A regression analysis of the mean
methylation levels of all samples, which diminishes the
influence of outliers, results in an even better concor-
dance (r
2 = 0.957, slope: 0.9317, 95% confidence interval:
0.9078 to 0.9556, data not shown). The results of the
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Figure 2 Cross-validation of 454 sequencing and conventional pyrosequencing: mean methylation level.C o m p a r i s o no fm e a n
methylation levels for all genes in all samples: pyrosequencing and 454 sequencing data show an excellent congruence. The sequencing result
of one sample (marked by an asterisk) did not pass the quality control (see Materials and Methods) and was not included in the figure. Grey
columns: 454 sequencing, black columns: pyrosequencing.
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Figure 3 Cross-validation of 454 sequencing and conventional pyrosequencing: individual methylation levels. Comparison of the
methylation levels of individual CpG dinucleotides of selected genes in selected samples: Even samples with a very heterogeneous methylation
pattern (e.g. p16
INK4A) display an excellent congruence. (■) 454 sequencing, (●) pyrosequencing.
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Figure 4 Comparison of pyrosequencing and 454 sequencing
using Bland-Altman Plots. Bland-Altman-Plot: Difference in
methylation level obtained by both methods versus the mean of
the methylation level for all 12 loci in all 10 samples. The individual
Bland-Altman-Plots can be found in the Additional File 3. The upper
and lower dotted lines indicate the 95% tolerance interval.
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Figure 5 Comparison of pyrosequencing and 454 sequencing
using regression analysis. Regression analysis was performed for
all individual measurements (methylation level of each individual
CpG site under study, n = 869) obtained by the two methods. The
excellent concordance of both methods is obvious (r
2 = 0.927, p <
0.0001, slope: 0.918, 95% confidence interval: 0.9067 to 0.9300).
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Page 5 of 10regression analysis performed for all 12 loci individually
are shown in Additional File 4.
Calculating the differences in relative methylation
obtained by the two methods for each individual CpG
site under study, revealed that for the vast majority of
measurements (720/869, 82.8%) a good congruence (i.e.,
less than 10 percentage points deviation) was observed.
514 out of 869 measurements (59.1%) gave a very good
congruence (i.e., less than 5 percentage points devia-
tion), 288/869 measurements (33.1%) a perfect match
with less than 2 percentage points deviation. For more
details see Additional File 5.
Analysis of the miR-663 gene gave the worst congru-
ence between pyrosequencing and 454 sequencing. The
most likely reason for this is the very low number of
454 sequence reads obtained for this locus. This low
efficiency is most probably due to the length of the
amplicon (with 312 bp the longest in this study), the
tendency to form secondary structures (see Additional
File 1) and the extremely high GC content of this locus
(%GC: 62.2%, CpGobs/CpGexp:0 . 9 4 ) ,w h i c ha l s om a d e
the design of a conventional pyrosequencing assay diffi-
cult. One sample (HCC 9) for miR-663 was left out
from analysis because the quality control criteria of the
methylation data analysis software were not met (see
also legend to Figure 2). Sample 8 and 10 also yielded
only 2 sequences each, and were left out from further
statistical analyses. Therefore, the total number of CpG
sites under study is 869 (and not 890). Figure 6 shows
clearly a correlation between number of reads per
amplicon and the congruence of both methods: High
read numbers result in better congruence. The samples
with a difference between both methods outside the
95% confidence interval all have low read numbers
(below 175).
Therefore, a minimum of 100 - 150 reads per ampli-
con should be achieved for proper quantification of
methylation levels be 454 sequencing. Using a full GS20
plate approximately 30 genes in 100 samples could be
analyzed in a single run. In contrast to pyrosequencing,
which provides an average methylation level for each
CpG dinucleotide across a possibly very heterogeneous
population of individual DNA molecules, 454 sequen-
c i n gd e l i v e r sas i n g l em o l e c u l e resolution. This reveals,
for example, that only very few completely methylated
LINE-1 alleles can be found, whereas for the MINT1
locus a substantial amount of individual alleles is fully
methylated (Additional File 6). Other genes display a
remarkable heterogeneity in the pattern of DNA methy-
lation across samples: RASSF1A for example displays in
some samples (with very few exceptions) only fully
methylated or fully unmethylated alleles whereas in
other samples a much more diverse pattern is found
(Additional File 7).
Discussion
Large scale methylome studies become more and more
important in biomedical sciences and high throughput
sequencing technologies promise large scale sensitive,
quantitative and high resolution DNA methylation ana-
lysis. However, the reliability of the quantification of the
methylation level of individual CpG sites by these new
sequencing technologies has not been explored compre-
hensively. Therefore, we compared massive parallel
bisulfite sequencing using 454 technology with conven-
tional pyrosequencing. The reliability of conventional
pyrosequencing has already been demonstrated in sev-
eral comparative studies by comparing the results with
the output of other methodologies (e.g., SnaPShot [20]
or COBRA [5] or by analyzing samples with defined
methylation status, like cell line DNA [21]. The repro-
ducibility of conventional bisulfite pyrosequencing tech-
nology proved to be excellent [8,22].
Despite the fact that several studies already describe
the use of 454 bisulfite sequencing for quantitative ana-
lysis of methylation data (see below) no comprehensive
comparison of these methodologies has been performed
so far:
In their pioneering study, Taylor et al. [23] compared
methylation data from 454 sequencing, qMSP and con-
ventional bisulfite sequencing for three genes. The data
were obtained from the analysis of three sample pools
and in vitro methylated DNA (Figure 3 in Taylor et al.).
Since no statistical analysis is presented in this publica-
tion, the extent of congruence seems to be judged by
visual inspection of the figures. Ordway et al. [24] com-
pared the mean methylation level obtained by 454
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Figure 6 Relationship between congruence and coverage.T h e
difference between both methods (as a measure of congruence)
was plotted against the number of reads obtained by 454
sequencing. Above coverage of 175 reads per sample no difference
lies outside the 95% confidence interval.
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sured by real-time PCR for four genes and found a rea-
sonable correlation (r
2: 0.45 - 0.87) with respect to this
average value (Figure 5, A, C, E, G in Ordway et al.).
Xie et al. [25] also compared the mean methylation level
obtained by 454 sequencing for various Alu elements
with the mean methylation level obtained by conven-
tional pyrosequencing (Figure 4 in Xie et al.). For six
loci sufficient data were available for a comparison. The
outcome was quite variable, from perfect congruence to
clear discordance (e.g., 25% versus 65%). One reason
might be the sequence heterogeneity even within sub-
groups of Alu elements [26]. Varlay et al. [27] compared
454 sequencing data to COBRA results from the same
sample for 14 tumors. All samples classified as “methy-
lated” by COBRA had a substantial proportion of mole-
cules (> 15%) with dense methylation in the proximal
promoter. The authors defined “dense methylation” as
“greater than 50% of CpGs methylated” (Table 1 in Var-
ley et al.). Since no details of the evaluation of the
COBRA data are given and no primary COBRA data are
displayed, a comprehensive judgment of the degree of
congruence is not possible .A l s o ,n oc o m p a r i s o nf o r
individual CpG dinucleotides has been performed. Kor-
shunowa et al. [28] describe no cross-validation in their
study, but this manuscript is from the same group as
the above cited publication from Ordway et al. [24].
Therefore, the results are indirectly linked to the com-
parison described in the latter study. Zeschnigk et al.
[29] compared the overall methylation pattern of
selected CpG islands obtained by 454 sequencing with
the results of conventional bisulfite sequencing. Since
they were interested in global methylation patterns, a
systematic comparison of methylation levels of indivi-
dual CpG dinucleotides was not performed. Further, the
low coverage achieved in this study (less than 10 reads
for the vast majority of CGIs and approx. 10 cloned
P C Rf r a g m e n t sp e rl o c u s )d i dn o tp e r m i tap r e c i s e
quantification with single-CpG resolution. Hodges et al.
[30] compared high throughput sequencing data
obtained by an Illumina GA2 platform with conven-
tional bisulfite sequencing of individual clones. For the
majority of the CpG sites under study the 90% confi-
dence intervals overlap, but the deviation of the calcu-
lated methylation levels is much larger than in this
study (supplementary Table two in Hodges et al.). How-
ever, these data are not directly comparable since sam-
ple preparation, primary output and subsequent data
processing are quite different from the 454 sequencing
platform.
One limitation of 454 sequencing is the accurate reso-
lution of homopolymer sequences. Because there is no
terminating moiety preventing multiple repeated incor-
porations at a given nucleotide injection cycle, the
length of a homopolymeric stretch must be inferred
from the signal intensity. This is prone to a greater
error rate than the discrimination of incorporation ver-
sus non-incorporation [31]. However, the quantification
tool for methylation analysis used in this study (QUMA,
[32]) was able to accurately align the fragments even if
there were gaps present in a homopolymeric region. A
few amplicons did not produce a sufficient number of
high-quality reads for the quantification of cytosine
methylation (i.e., miR-663). This may be due to the
amplification bias at the library preparation step, result-
ing in a bias of the fragments generated during the
emulsion PCR reaction. However, an insufficient num-
ber of reads was obtained for only 3 of the 120 ampli-
cons (2.5%).
A clear advantage of 454 sequencing is the higher sen-
sitivity for the detection of low level methylation. The
1.4% of fully methylated LINE-1 alleles detected in sam-
ple no. 8 (see Additional File 6) are not detectable by
conventional pyrosequencing due to the inherent back-
ground. Depending on the quality of the assay the back-
ground signals are in the range of several percentage
points. Since the vast majority of LINE-1 sequences are
more than 90% similar to each other in the CpG islands
contained within the 5’-UTR, a detailed analysis of the
different LINE-1 family members would require the
amplification and sequencing of much larger regions.
However, these other, more diverse regions do not qua-
lify as CpG islands and are most likely not directly
affected by differential methylation.
Our data demonstrate that the two different meth-
odologies yielded very similar methylation values
obtained for the large majority of CpG sites (82.8%)
even for very heterogeneous methylation patterns as
exemplified by the p16
INK4a gene (range of methylation
levels of individual CpG dinucleotides: 10 - 70%, see
Figure 3). Further, for low level methylation levels as
seen in miR-34a, a very high congruence was achieved.
This remarkable concordance serves as a powerful vali-
dation for both technical approaches which has not pre-
viously been demonstrated.
Conclusion
The 454 technology enables a much more comprehen-
sive coverage of whole CpG islands and the single mole-
cule resolution provides unprecedented information
about the heterogeneity of methylation patterns (a few
examples are provided in Additional File 7). It also
offers the possibility of studying many loci in parallel.
These advantages come with a considerable initial
investment, expansive reagents, low turn-around time,
and a time-consuming data processing and evaluation
step, making it primarily a research tool. By contrast,
conventional pyrosequencing is generally much faster,
Potapova et al. BMC Biotechnology 2011, 11:6
http://www.biomedcentral.com/1472-6750/11/6
Page 7 of 10easier and cheaper. Provided that only a single locus has
to be analyzed at regular intervals, and that the differen-
tially methylated region of interest is well characterized
and quite small, as is the case for routine diagnostic
applications (e.g., analyzing MGMT gene methylation in
glioblastoma [33] or hMLH1 gene methylation in color-
ectal carcinoma [34]) conventional pyrosequencing
remains the method of choice.
Therefore, in our opinion conventional pyrosequen-
cing and 454 sequencing are not competing but comple-
mentary methodologies fulfilling different functions in
the field of DNA methylation analysis.
Methods
Tissue specimens and bisulfite modification of DNA
All hepatocellular carcinoma (HCC) samples were
retrieved from the archive of the Institute of Pathology,
Hanover Medical School (Germany) and analyzed anon-
ymously following the guidelines of the local Ethics
committee ("Ethik-Kommission der Medizinischen
Hochschule Hannover”, head: Prof. Dr. Tröger). Tumor
cell content was determined to be greater than 70%.
DNA was isolated by digestion with proteinase K
(Merck, Darmstadt, Germany) followed by phenol/
chloroform extraction from a total of 10 specimens
(Additional File 8). Genomic DNA (1 μg) from tumor
specimens was treated with sodium bisulfite using the
Imprint™ DNA Modification Kit (Sigma, Saint Louis,
Missouri) following the protocol supplied by the
manufacturer.
Primer design and PCR
Specific primers were designed for 12 loci using publicly
available software (http://www.genelink.com). A ten or
nine-nucleotide sample-specific tag was added to the 5’
end of each forward primer sequence so that each sam-
ple could be computationally separated after 454
sequencing analysis. The tag sequences were provided
by Roche (Mannheim, Germany). PCR was performed
for 33 – 36 cycles in a 50 μl reaction using annealing
temperatures from 60°C to 65°C, depending on the
locus under study. A complete list of the 120 primer
pairs is available in Additional File 9. Denaturation (95°
C), annealing, and extension (72°C) times were 30 s,
45 s, and 1 min, respectively. Each amplicon was indivi-
dually prepared, gel purified, and quantified by Quant-
IT PicoGreen kit (Invitrogen, Eugene, Oregon).
454 sequencing
F o ras i n g l e4 5 4s e q u e n c i ng run one hundred twenty
amplicons were pooled in equimolar amounts in a single
tube. For some amplicons a precipitation step was
necessary to increase the concentration. This was per-
formed following standard procedures using ethanol and
sodium acetate and glycogen (Sigma, Saint Louis,
Missouri) as a carrier. The emulsion PCR and subse-
quent sequencing reaction were performed exactly as
described in the GS FLX emPCR Method Manual
(USM-00033.A, Roche, Mannheim, Germany).
One region of a PicoTiterPlate (25×75) was used with
GS FLX-chemistry. Using this configuration the
expected yield is approx. 70,000 reads and 17.5 Mbp
sequence content in total.
Methylation analysis using Pyrosequencing
PCR products were generated in a 25 μL reaction
volume with 400 nmol/L of forward, 40 nmol/L reverse
and 400 nmol/L universal biotinylated primers, 200
μmol/L of each dNTP, 1.5 mmol/L or 2.5 mmol/L
MgCl2 (see Additional FIle 9 for all primer sequences
and reaction conditions), 1x Platinum-Taq reaction buf-
fer and 1.25 units PlatinumTaq™ (Invitrogen, Karlsruhe,
Germany). PCR conditions were 95°C for 5 minutes, fol-
lowed by 45 cycles with denaturation at 95°C for 30 sec-
onds, annealing at 55°C or 60°C for 45 seconds, and
elongation at 72°C for 30 seconds finished with 1 cycle
final elongation at 72°C for 5 minutes. The reverse pri-
mer is tagged by a sequence recognized by the universal
primer. Therefore, a single (expansive) biotinylated pri-
mer can be used for all different gene-specific assays
[21].
PCR products (5-20 μL) were added to a mix consist-
ing of 3 μL Streptavidin Sepharose HP™ (Amersham
Biosciences, Freiburg, Germany) and 37 μL binding buf-
fer (Qiagen, Hilden, Germany) and mixed at 1200 rpm
for 5 minutes at room temperature.
Using the Vacuum Prep Tool™ (Qiagen, Hilden,
Germany), single-stranded PCR products were prepared
following the manufacturer’s instructions. The sepharose
beads with the single stranded templates attached were
released into a PSQ 96 Plate Low™ (Qiagen, Hilden,
Germany) containing a mix of 12 μLa n n e a l i n gb u f f e r
(Qiagen, Hilden, Germany) and 500 nmmol/L of the
corresponding sequencing primer (see Additional File
9). Pyrosequencing™ reactions were performed in a
PyroMark MD System (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions using the
PyroGold SQA™ Reagent Kit (Qiagen, Hilden,
Germany). CpG site quantification was performed using
the methylation Software Pyro Q-CpG™.
Sequence analysis
59,366 reads were obtained from a single run. All the
454 sequences came in one large FASTA file with one
sequence read per entry. The sequences were from the
forward strand. The primers were composed of a 9-10
nucleotide initial sequence used as a tag to identify the
sample. Primary analysis of the sequencing results was
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sequence software Galaxy (http://main.g2.bx.psu.edu/).
Each amplicon sequence was assigned to 1 of the 12 loci
under study based on the tagged locus-specific primers.
To determine sequence identity, sodium bisulfite conver-
sion efficiency and the methylation state for each CpG
site, the amplicon sequences were analyzed by using a
web-based freely available quantification tool for methy-
lation analysis (QUMA, [32]). The percent identity scores
were set at 90% and CpH conversion efficiency were set
at 100%. The sequences were then filtered at 90%
sequence identity and 100% CpH conversion efficiency.
Statistical analyses were carried out using Microsoft
Excel, GraphPad Prism5 and QUMA [32] software.
For the comparison of the two methods Bland-Alt-
man-Plots were generated [35]. In these plots the differ-
ence of two methods is plotted against the average of
both methods. A comprehensive description of this type
of data presentation by Altman and Bland ("Measure-
ments in Medicine: the Analysis of Method Comparison
Studies”, The Statistician 32 (1983) 307 - 317) can be
found freely available at: https://person.hst.aau.dk/slc/
Teaching/Papers/BlandAltman83.pdf
Additional material
Additional File 1: Number of reads for all loci in all 10 HCC
specimens
Additional File 2: Relationship between number of reads per
sample and amplicon length, secondary structure formation, and
GC content.
Additional File 3: Bland-Altman Plots for all 12 loci separately.
Additional File 4: Regression analysis for all 12 loci separately.
Additional File 5: Detailed description of differences between 454
sequencing and conventional pyrosequencing.
Additional File 6: Example for details obtained only by 454
sequencing: Exact determination of the number of fully methylated
alleles.
Additional File 7: Example for details obtained only by 454
sequencing: “Heterogeneous” methylation patterns versus
dichotomous patterns ("fully methylated or fully unmethylated”).
Additional File 8: HCC specimens under study.
Additional File 9: Primer sequences.
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qMSP: quantitative Methylation-specific PCR
Acknowledgements
The authors would like to thank Jeanette Poczkaj and Elisa Schipper for
expert technical assistance and Tim Keys for carefully copyediting the text.
This work was supported by a grant from the “Deutsche
Forschungsgemeinschaft” (SFB/TRR77 “Liver Cancer, project B1)
Author details
1Institute of Pathology, Medizinische Hochschule Hannover, D-30625
Hannover, Germany.
2Institute of Biometrics, Medizinische Hochschule
Hannover, D-30625 Hannover, Germany.
3Institute of Medical Microbiology
and Hospital Epidemiology, Medizinische Hochschule Hannover, D-30625
Hannover, Germany.
Authors’ contributions
UL, AP and HK conceived the study; AP, CA, and BH performed all
experiments prior to 454 sequencing; SL established and performed the 454
sequencing under the guidance of SS; AP, CA, and UL analyzed the 454 and
the pyrosequencing data; KH performed the statistical analysis; HK selected
and evaluated all cases; UL and AP wrote the manuscript with support from
HK, BH, and SS. All authors read and approved the final manuscript.
Received: 27 August 2010 Accepted: 14 January 2011
Published: 14 January 2011
References
1. Ting AH, McGarvey KM, Baylin SB: The cancer epigenome–components
and functional correlates. Genes Dev 2006, 20(23):3215-3231.
2. Robertson KD: DNA methylation and chromatin - unraveling the tangled
web. Oncogene 2002, 21(35):5361-5379.
3. Laird PW: The power and the promise of DNA methylation markers. Nat
Rev Cancer 2003, 3(4):253-266.
4. Zuo T, Tycko B, Liu TM, Lin HJ, Huang TH: Methods in DNA methylation
profiling. Epigenomics 2009, 1(2):331-345.
5. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation
assay. Nucleic Acids Res 1997, 25(12):2532-2534.
6. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G,
Cantor CR, Field JK, van den Boom D: Quantitative high-throughput
analysis of DNA methylation patterns by base-specific cleavage and
mass spectrometry. Proc Natl Acad Sci USA 2005, 102(44):15785-15790.
7. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D,
Danenberg PV, Laird PW: MethyLight: a high-throughput assay to
measure DNA methylation. Nucleic Acids Res 2000, 28(8):E32.
8. Dupont JM, Tost J, Jammes H, Gut IG: De novo quantitative bisulfite
sequencing using the pyrosequencing technology. Anal Biochem 2004,
333(1):119-127.
9. Liu L, Wylie RC, Hansen NJ, Andrews LG, Tollefsbol TO: Profiling DNA
methylation by bisulfite genomic sequencing: problems and solutions.
Methods Mol Biol 2004, 287:169-179.
10. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J,
Braverman MS, Chen YJ, Chen Z, et al: Genome sequencing in
microfabricated high-density picolitre reactors. Nature 2005,
437(7057):376-380.
11. Chun J, Kim KY, Lee JH, Choi Y: The analysis of oral microbial
communities of wild-type and toll-like receptor 2-deficient mice using a
454 GS FLX Titanium pyrosequencer. BMC Microbiol 2010, 10:101.
12. Tischoff I, Tannapfe A: DNA methylation in hepatocellular carcinoma.
World J Gastroenterol 2008, 14(11):1741-1748.
13. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP: DNA
methylation and environmental exposures in human hepatocellular
carcinoma. J Natl Cancer Inst 2002, 94(10):755-761.
14. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG,
Volinia S, Croce CM, Schmittgen TD, et al: Methylation mediated silencing
of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer
Res 2008, 68(13):5049-5058.
15. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH: Aberrant CpG island
hypermethylation along multistep hepatocarcinogenesis. Am J Pathol
2003, 163(4):1371-1378.
16. Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, Wei L: CpG
island methylator phenotype association with upregulated telomerase
activity in hepatocellular carcinoma. Int J Cancer 2008, 123(5):998-1004.
17. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, Li K, Wei L: CpG island
methylator phenotype association with elevated serum alpha-
fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007,
13(3):944-952.
18. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A:
Methylation-mediated silencing of SOCS-1 gene in hepatocellular
carcinoma derived from cirrhosis. Clin Cancer Res 2003, 9(14):5295-5298.
19. Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A,
Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S: Precision of
pyrosequencing assay to measure LINE-1 methylation in colon cancer,
Potapova et al. BMC Biotechnology 2011, 11:6
http://www.biomedcentral.com/1472-6750/11/6
Page 9 of 10normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010,
12(2):177-183.
20. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P: Evaluation of a
potential epigenetic biomarker by quantitative methyl-single nucleotide
polymorphism analysis. Electrophoresis 2002, 23(24):4072-4079.
21. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative
universal Pyrosequencing methylation analysis of CpG sites.
Biotechniques 2003, 35(1):146-150.
22. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple
methylation variable positions in CpG islands by Pyrosequencing.
Biotechniques 2003, 35(1):152-156.
23. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, Caldwell CW, Shi H:
Ultradeep bisulfite sequencing analysis of DNA methylation patterns in
multiple gene promoters by 454 sequencing. Cancer Res 2007,
67(18):8511-8518.
24. Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW,
Bacher B, Peterson S, Rohlfing T, Hall J, et al: Identification of novel high-
frequency DNA methylation changes in breast cancer. PLoS One 2007,
2(12):e1314.
25. Xie H, Wang M, Bonaldo Mde F, Smith C, Rajaram V, Goldman S, Tomita T,
Soares MB: High-throughput sequence-based epigenomic analysis of Alu
repeats in human cerebellum. Nucleic Acids Res 2009, 37(13):4331-4340.
26. Cordaux R, Batzer MA: The impact of retrotransposons on human
genome evolution. Nat Rev Genet 2009, 10(10):691-703.
27. Varley KE, Mutch DG, Edmonston TB, Goodfellow PJ, Mitra RD: Intra-tumor
heterogeneity of MLH1 promoter methylation revealed by deep single
molecule bisulfite sequencing. Nucleic Acids Res 2009, 37(14):4603-4612.
28. Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A,
Ordway JM, McCombie WR, Leon J, Jeddeloh JA, et al: Massively parallel
bisulphite pyrosequencing reveals the molecular complexity of breast
cancer-associated cytosine-methylation patterns obtained from tissue
and serum DNA. Genome Res 2008, 18(1):19-29.
29. Zeschnigk M, Martin M, Betzl G, Kalbe A, Sirsch C, Buiting K, Gross S,
Fritzilas E, Frey B, Rahmann S, et al: Massive parallel bisulfite sequencing
of CG-rich DNA fragments reveals that methylation of many X-
chromosomal CpG islands in female blood DNA is incomplete. Hum Mol
Genet 2009, 18(8):1439-1448.
30. Hodges E, Smith AD, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang MQ, Ye K,
Bhattacharjee A, Brizuela L, et al: High definition profiling of mammalian
DNA methylation by array capture and single molecule bisulfite
sequencing. Genome Res 2009, 19(9):1593-1605.
31. Shendure J, Ji H: Next-generation DNA sequencing. Nat Biotechnol 2008,
26(10):1135-1145.
32. Kumaki Y, Oda M, Okano M: QUMA: quantification tool for methylation
analysis. Nucleic Acids Res 2008, , 36 Web Server: W170-175.
33. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W,
Hegi ME: MGMT promoter methylation in malignant gliomas: ready for
personalized medicine? Nat Rev Neurol 2010, 6(1):39-51.
34. Hitchins MP, Ward RL: Constitutional (germline) MLH1 epimutation as an
aetiological mechanism for hereditary non-polyposis colorectal cancer. J
Med Genet 2009, 46(12):793-802.
35. Bland JM, Altman DG: Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986,
1(8476):307-310.
doi:10.1186/1472-6750-11-6
Cite this article as: Potapova et al.: Systematic cross-validation of 454
sequencing and pyrosequencing for the exact quantification of DNA
methylation patterns with single CpG resolution. BMC Biotechnology
2011 11:6. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Potapova et al. BMC Biotechnology 2011, 11:6
http://www.biomedcentral.com/1472-6750/11/6
Page 10 of 10